Sampatrilat (BioDeep_00000183142)
human metabolite blood metabolite
代谢物信息卡片
化学式: C26H40N4O9S (584.2515870000001)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 45.19%
分子结构信息
SMILES: CS(=O)(=O)NC(CCCCN)C(=O)NCC(CC1(CCCC1)C(=O)NC(CC1=CC=C(O)C=C1)C(O)=O)C(O)=O
InChI: InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)
描述信息
同义名列表
7 个代谢物同义名
3-[(6-Amino-1-hydroxy-2-methanesulphonamidohexylidene)amino]-2-[(1-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}cyclopentyl)methyl]propanoic acid; 3-[(6-Amino-1-hydroxy-2-methanesulphonamidohexylidene)amino]-2-[(1-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}cyclopentyl)methyl]propanoate; 3-[(6-Amino-1-hydroxy-2-methanesulfonamidohexylidene)amino]-2-[(1-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}cyclopentyl)methyl]propanoate; 3-(6-amino-2-methanesulfonamidohexanamido)-2-[(1-{[1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}cyclopentyl)methyl]propanoic acid; N-[1-(2-Carboxy-3-{[N~2~-(methanesulfonyl)lysyl]amino}propyl)cyclopentane-1-carbonyl]tyrosine; N-(1-(2-Carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine; Sampatrilat
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Rong-Kun Chang, Amir H Shojaei. Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2004 Jan; 7(1):8-12. doi:
NULL. [PMID: 15144729] - G R Norton, A J Woodiwiss, C Hartford, B Trifunovic, S Middlemost, A Lee, M J Allen. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
American journal of hypertension.
1999 Jun; 12(6):563-71. doi:
10.1016/s0895-7061(99)00009-6. [PMID: 10371365] - E J Wallis, L E Ramsay, J Hettiarachchi. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Clinical pharmacology and therapeutics.
1998 Oct; 64(4):439-49. doi:
10.1016/s0009-9236(98)90075-3. [PMID: 9797801] - R F Venn, B Kaye, P V Macrae, K C Saunders. Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Journal of pharmaceutical and biomedical analysis.
1998 Jan; 16(5):875-81. doi:
10.1016/s0731-7085(97)00126-x. [PMID: 9535199] - R F Venn, G Barnard, B Kaye, P V Macrae, K C Saunders. Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Journal of pharmaceutical and biomedical analysis.
1998 Jan; 16(5):883-92. doi:
10.1016/s0731-7085(97)00127-1. [PMID: 9535200]